Đang chuẩn bị liên kết để tải về tài liệu:
Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Lenalidomide has been approved for the treatment of lower-risk myelodysplastic syndrome (MDS) with 5q deletion (del(5q)). We present for the first time a retrospective analysis of low-risk MDS with isolated del5q treated with lenalidomide, outside the clinical trials. |

TÀI LIỆU LIÊN QUAN

A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: The PolExPIR study

Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: A single-center experience

Isolated central nervous system relapses in patients with high-risk neuroblastoma -clinical presentation and prognosis: Experience of the Polish Paediatric Solid Tumours Study Group

Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)